Search research articles
Contact Us
Filters
Showing results (51-60 of 434) with videos related to
Page
of 44
Sort By:
The Oncologist
|
June 19, 2016
DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities
Mallika Dhawan, Charles J Ryan, Alan Ashworth
BMC Molecular Biology
|
October 24, 2002
Retroviral vectors for establishing tetracycline-regulated gene expression in an otherwise recalcitrant cell line
Paraic A Kenny, Tariq Enver, Alan Ashworth
Nature Reviews. Clinical Oncology
|
August 12, 2010
Making the best of PARP inhibitors in ovarian cancer
Susana Banerjee, Stan B Kaye, Alan Ashworth
Critical Reviews in Oncology/Hematology
|
December 10, 2016
PARP inhibitor combination therapy
Amy Dréan, Christopher J Lord, Alan Ashworth
Cell Cycle (Georgetown, Tex.)
|
July 8, 2008
Dissecting resistance to endocrine therapy in breast cancer
Christopher J Lord, Elizabeth Iorns, Alan Ashworth
The Biochemical Journal
|
November 4, 2008
Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization
Elizabeth Iorns, Christopher J Lord, Alan Ashworth
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2006
Targeting the double-strand DNA break repair pathway as a therapeutic strategy
Christopher J Lord, Michelle D Garrett, Alan Ashworth
NPJ Breast Cancer
|
April 6, 2023
Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology
Divneet Mandair, Jorge S Reis-Filho, Alan Ashworth
Cancer Cell
|
September 10, 2014
DAISY: picking synthetic lethals from cancer genomes
Colm J Ryan, Christopher J Lord, Alan Ashworth
Current Opinion in Genetics & Development
|
March 18, 2008
DNA repair deficiency as a therapeutic target in cancer
Sarah A Martin, Christopher J Lord, Alan Ashworth
Page
of 44
Search research articles
Search
Showing results (51-60 of 434) with videos related to
Sort By:
Page
of 44
The Oncologist
|
June 19, 2016
DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities
Mallika Dhawan, Charles J Ryan, Alan Ashworth
BMC Molecular Biology
|
October 24, 2002
Retroviral vectors for establishing tetracycline-regulated gene expression in an otherwise recalcitrant cell line
Paraic A Kenny, Tariq Enver, Alan Ashworth
Nature Reviews. Clinical Oncology
|
August 12, 2010
Making the best of PARP inhibitors in ovarian cancer
Susana Banerjee, Stan B Kaye, Alan Ashworth
Critical Reviews in Oncology/Hematology
|
December 10, 2016
PARP inhibitor combination therapy
Amy Dréan, Christopher J Lord, Alan Ashworth
Cell Cycle (Georgetown, Tex.)
|
July 8, 2008
Dissecting resistance to endocrine therapy in breast cancer
Christopher J Lord, Elizabeth Iorns, Alan Ashworth
The Biochemical Journal
|
November 4, 2008
Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization
Elizabeth Iorns, Christopher J Lord, Alan Ashworth
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2006
Targeting the double-strand DNA break repair pathway as a therapeutic strategy
Christopher J Lord, Michelle D Garrett, Alan Ashworth
NPJ Breast Cancer
|
April 6, 2023
Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology
Divneet Mandair, Jorge S Reis-Filho, Alan Ashworth
Cancer Cell
|
September 10, 2014
DAISY: picking synthetic lethals from cancer genomes
Colm J Ryan, Christopher J Lord, Alan Ashworth
Current Opinion in Genetics & Development
|
March 18, 2008
DNA repair deficiency as a therapeutic target in cancer
Sarah A Martin, Christopher J Lord, Alan Ashworth
Page
of 44